CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
SmokingTobacco UseTobacco Smoking
Interventions
OTHER

Product A

Usual brand (UB) filtered, combustible cigarette

OTHER

Product B

Nicorette® Mint 4 mg nicotine lozenge

OTHER

Product C

CSD1903-11, a hard nicotine lozenge, 2 mg nicotine

OTHER

Product D

CSD1903-11, a hard nicotine lozenge, 4 mg nicotine

OTHER

Product E

CSD1903-11, a hard nicotine lozenge, 8 mg nicotine

OTHER

Product F

CSD1903-12, a soft nicotine lozenge, 2 mg nicotine

OTHER

Product G

CSD1903-12, a soft nicotine lozenge, 4 mg nicotine

OTHER

Product H

CSD1903-12, a soft nicotine lozenge, 8 mg nicotine

Trial Locations (1)

27265

High Point Clinical Trials Center, High Point

All Listed Sponsors
lead

RAI Services Company

INDUSTRY

NCT04167384 - CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products | Biotech Hunter | Biotech Hunter